A review of clinical trials of therapies for osteoporosis using fracture as an end point (Q33839504)

29 July 2017

0 references

A review of clinical trials of therapies for osteoporosis using fracture as an end point (English)

1 reference

29 July 2017

0 references

1 reference

Blank RD

1

1 reference

29 July 2017

Bockman RS

series ordinal

2

1 reference

29 July 2017

publication date

1 January 1999

1 reference

Journal of Clinical Densitometry

29 July 2017

published in

1 reference

29 July 2017

volume

2

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

435-452

1 reference

A model of lifetime osteoporosis impact

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Bone mass measurement: prediction of risk

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Correcting calcium nutritional deficiency prevents spine fractures in elderly women.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Calcium for prevention of osteoporotic fractures in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Vitamin D3 and calcium to prevent hip fractures in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Action of 1,25-dihydroxyvitamin D3 on calcium balance and bone turnover and its effect on vertebral fracture rate

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Treatment of postmenopausal osteoporosis with calcitriol or calcium

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Prevention of spinal osteoporosis in oophorectomised women

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Treatment of postmenopausal osteoporosis with transdermal estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

The risk of hip fracture in postmenopausal females with or without estrogen drug exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Menopausal estrogen therapy and hip fractures

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Fracture protection provided by long-term estrogen treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

The effect of fluoride and calcium on spinal bone mineral content: a controlled, prospective (3 years) study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Increased incidence of hip fracture in osteoporotic women treated with sodium fluoride

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Short-term effects of synthetic human parathyroid hormone-(1--34) administration on bone mineral metabolism in osteoporotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Pre-existing fractures and bone mass predict vertebral fracture incidence in women

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Bone mass and beyond: risk factors for fractures

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Treatable and untreatable risk factors for hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Prediction of fracture risk. II: Other risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

The association of radiographically detected vertebral fractures with back pain and function: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1094-6950%2806%2960409-5

7 January 2021

10.1016/S1094-6950(06)60409-5

Identifiers

DOI

1 reference

29 July 2017

1 reference